Citigroup Initiates Coverage of Agilent with Buy Rating | GenomeWeb

NEW YORK (GenomeWeb News) – Citigroup today initiated coverage of Agilent Technologies with a Buy rating and a $46 target on the company's stock.

In a research note, analyst Amit Bhalla said that he expects revenues to grow between 5 percent and 6 percent through fiscal 2014 with EPS growth of between 10 and 11 percent. He also noted Agilent's growing footprint in the life sciences, as well as its comparatively lighter exposure to the academic/government end markets and greater presence in the emerging markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.